The phase III MYSTIC trial assessed the first-line efficacy of the anti-PD-L1 agent durvalumab – given alone or alongside the CTLA-4 blocker tremelimumab – versus platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer. The combination failed to show a significant progression-free or overall survival benefit, but additional analyses of the trial are ongoing.
One such analysis, focusing on identifying mutations that could predict sensitivity or resistance to immunotherapy, was presented at WCLC 2019:
Title: Mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: Analysis from the MYSTIC trial
Presenter: Naiyer Rizvi, Columbia University Medical Center, New York, USA
Sunday, September 8: 16:20–16:30 (Abstract OA04.07)